Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New System to Improve DNA Sequencing

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
A sensing system developed at Cambridge is being commercialised in the UK for use in rapid, low-cost DNA sequencing.

System would make the prediction and diagnosis of disease more efficient and individualised treatment more affordable.

Dr Ulrich Keyser of the University’s Cavendish Laboratory, along with PhD student Nick Bell and other colleagues, has developed a system which combines a solid-state nanopore with a technique known as DNA origami, for use in DNA sequencing, protein sensing and other applications. The technology has been licensed for development and commercialisation to UK-based company Oxford Nanopore, which is developing portable, low-cost DNA analysis sequencing devices.

Nanopore technology has the potential to revolutionise DNA sequencing and the analysis of a range of other biological molecules, providing dramatic improvements in power, cost and speed over current methods.

A nanopore is an extremely small hole - between one and 100 nanometres in diameter – typically contained in a membrane between two chambers containing a salt solution and the molecule of interest. When the molecules pass through the nanopores, they disrupt an ionic current through the nanopore and this difference in electrical signals allows researchers to determine certain properties of those molecules.

Over the past decade, researchers have been investigating various methods of constructing nanopores in order to improve accuracy and reliability. A key part of this is the ability to finely control the shape and surface chemistry of the nanopores, which would maximise sensitivity and facilitate the identification of a wider range of molecules.

Currently, there are two main types of nanopores in use: solid state nanopores constructed by fabricating tiny holes in silicon or graphene with electron beam equipment; and biological nanopores made by inserting pore-forming proteins into a biological membrane such as a lipid bilayer.

Biological nanopores are cheap and easy to manufacture in large quantities of identical pores.  It is possible through genetic engineering to define their structure at the atomic level, varying the pores for the analysis of different target molecules. However, they are only suitable for a limited range of applications, and may be replaced over time by solid-state nanopores. At present, solid-state nanopores are difficult to manufacture and are not as sensitive as biological nanopores, as it is difficult to position specific chemical groups on the surface.

In collaboration with researchers at Ludwig Maximilian University in Munich, Dr Keyser and his team have developed a hybrid nanopore which combines a solid-state material, such as silicon or graphene, and DNA origami - small, well-controlled shapes made of DNA.

“The DNA origami structures can be formed into any shape, allowing highly accurate control of the size and shape of the pore, so that only molecules of a certain shape can pass through,” says Dr Keyser. “This level of control allows for far more detailed analysis of the molecule, which is particularly important for applications such as phenotyping or gene sequencing.”

Since complementary sequences of DNA can bind to one another, the origami structures can be customised so that functional groups, fluorescent compounds and other molecular adapters can be added to the DNA strands with sub-nanometre precision, improving sensitivity and reliability. Additionally, hundreds of billions of self-assembling origami structures can be produced at the same time, with yields of up to 90 per cent.

Recent research by the team, published in the journal Lab on a Chip, has shown that up to 16 measurements can be taken simultaneously, allowing for much higher data throughput and screening of different DNA origami structures.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Consortium to Develop and Study Early Stage Drugs
An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.
Thursday, July 30, 2015
‘Mini-Lungs’ Grown To Aid The Study Of Cystic Fibrosis
'Mini-lungs’ have been created using stem cells derived from skin cells of patients with cystic fibrosis.
Thursday, March 19, 2015
Artificially-intelligent Robot Scientist ‘Eve’ Could Boost Search for New Drugs
Eve, an artificially-intelligent ‘robot scientist’ could make drug discovery faster and much cheaper, say researchers writing in the Royal Society journal Interface.
Wednesday, February 04, 2015
Drugging the Undruggable
Discovery opens up possibility of slowing cancer spread.
Wednesday, November 12, 2014
Discovery of New Structure of Cell’s Communication Channel Could Aid Drug Development
Researchers hope discovery will lead to improvements in drugs that act on the sodium channel to treat a range of cardiac and pain conditions.
Wednesday, April 30, 2014
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!